What are the recommended diagnostic steps and management strategies for complications of dengue infection?

Dengue Complications: Diagnosis and Management

For dengue complications, diagnose using time-based testing algorithms (NAAT/NS1 ≤7 days, IgM serology >7 days), and manage with judicious crystalloid resuscitation during the critical phase while monitoring for plasma leakage, severe bleeding, and organ dysfunction—avoiding both under- and over-resuscitation.

Diagnostic Approach

Timing-Based Testing Strategy

The diagnostic approach depends critically on symptom duration 1:

≤7 days from symptom onset:

• Perform dengue virus NAAT (RT-PCR) or NS1 antigen testing on serum
• NAAT can also be performed on plasma, whole blood, CSF, or urine
• Positive NAAT confirms acute dengue infection
• If negative, proceed to IgM serology

>7 days from symptom onset:

• Perform dengue virus IgM antibody testing on serum
• Positive IgM with negative NAAT requires confirmatory PRNT (plaque reduction neutralization test)
• PRNT titer ≥10 for dengue with <10 for Zika/other flaviviruses confirms recent dengue infection
• Negative IgM collected 7 days to 12 weeks post-onset rules out dengue

Key Diagnostic Pitfalls

Important caveat: In endemic areas with co-circulating Zika virus, always test for both dengue and Zika simultaneously, as cross-reactivity can confound IgM results 1. Without confirmatory PRNT, positive IgM may represent false-positive results or prior flavivirus exposure rather than acute infection.

For epidemiologically significant cases (first local transmission, unusual presentation), repeat positive NAAT on newly extracted RNA from the same specimen 1.

Clinical Severity Assessment and Risk Stratification

Classification System

Classify patients into three categories to guide management 2, 3:

1. Dengue without warning signs - outpatient management
2. Dengue with warning signs - hospitalization required
3. Severe dengue - intensive monitoring and aggressive intervention

Warning signs indicating hospitalization 4, 3:

• Abdominal pain or tenderness
• Persistent vomiting
• Clinical fluid accumulation (ascites, pleural effusion)
• Mucosal bleeding
• Lethargy or restlessness
• Liver enlargement >2 cm
• Rising hematocrit with rapid platelet decline

Severe dengue criteria 2, 4:

• Plasma leakage leading to shock or respiratory distress
• Severe bleeding (hematemesis, melena, menorrhagia)
• Organ impairment (AST/ALT >1000 IU/L, altered consciousness, myocarditis, acute kidney injury)

Point-of-Care Ultrasound for Early Detection

Structured POCUS protocol should assess 5:

• Gallbladder wall thickening (earliest sign of plasma leakage)
• Ascites (perihepatic, perisplenic, pelvic)
• Pleural effusions (bilateral assessment)
• Inferior vena cava diameter and collapsibility

These ultrasound findings often precede clinical manifestations of plasma leakage by hours and enable earlier intervention before shock develops 5. Serial POCUS combined with hematocrit and lactate measurements provides superior risk stratification compared to clinical assessment alone.

Management of Complications

Fluid Resuscitation Strategy

Crystalloids are the initial and preferred fluid 4, 3:

For patients with warning signs but no shock:

• Start isotonic crystalloids at 5-7 mL/kg/hour for 1-2 hours
• Reassess clinically and check hematocrit
• If improved: reduce to 3-5 mL/kg/hour for 2-4 hours, then 2-3 mL/kg/hour
• If worsening: increase to 10 mL/kg/hour for 1 hour

For dengue shock syndrome:

• Bolus 10-20 mL/kg isotonic crystalloid over 15-30 minutes
• Reassess after each bolus
• If no improvement after 2-3 boluses, consider colloids
• Monitor for fluid overload (increasing respiratory rate, oxygen desaturation, rising JVP)

Critical principle: Both under-resuscitation (leading to shock) and over-resuscitation (causing pulmonary edema, pleural effusion) are harmful 3. The critical phase typically lasts 24-48 hours; aggressive fluids are only needed during this window.

Transfusion Management

Platelet transfusion is NOT indicated prophylactically 4.

Transfuse platelets only when 2, 4:

• Active severe bleeding (hematemesis, melena, intracranial hemorrhage) regardless of platelet count
• Platelet count <10,000/μL with high bleeding risk
• Invasive procedures required with platelet count <50,000/μL

Red blood cell transfusion:

• For significant blood loss with hemodynamic instability
• Target hemoglobin >7 g/dL in stable patients, >9 g/dL in shock

Organ-Specific Complications

Hepatic involvement 4:

• Common with transaminitis (AST/ALT 100-1000 IU/L)
• Severe hepatitis (>1000 IU/L) requires N-acetylcysteine consideration
• Monitor for coagulopathy and hepatic encephalopathy

Neurological complications 6:

• Dengue encephalitis presents with altered consciousness, seizures
• CSF may show lymphocytic pleocytosis, elevated protein
• Brain MRI may show subtle changes in thalamus, basal ganglia, or white matter
• In immunocompromised patients (transplant recipients), initial dengue testing may be negative; repeat if high suspicion

Hemophagocytic lymphohistiocytosis (HLH) 7:

• Suspect when fever persists beyond critical phase with worsening cytopenias, rising ferritin (>10,000 ng/mL), hypertriglyceridemia, hypofibrinogenemia
• Bone marrow aspirate confirms hemophagocytosis
• Treat with dexamethasone 10 mg/m²/day for 14 days with tapering 7
• This is a potentially fatal complication requiring early recognition

Intravascular hemolysis 7:

• Rare complication presenting with hemoglobinuria, indirect hyperbilirubinemia, elevated LDH, negative direct antiglobulin test
• Supportive care with transfusion support and cautious fluid management

Monitoring Parameters

Serial monitoring during critical phase 8, 3:

• Hematocrit every 4-6 hours (rising hematocrit indicates plasma leakage)
• Platelet count daily
• Vital signs hourly in severe cases
• Urine output (maintain >0.5 mL/kg/hour)
• Serum lactate (elevated indicates tissue hypoperfusion)
• Liver enzymes, coagulation profile if bleeding or severe disease

Specific Considerations

No antiviral therapy is currently available 2, 4. Management remains entirely supportive. Avoid NSAIDs and aspirin due to bleeding risk; use acetaminophen for fever.

Biomarkers for severity prediction 8:

• C-reactive protein elevation
• Immature platelet fraction (IPF%)
• Ferritin >10,000 ng/mL suggests HLH

The triphasic course 2:

1. Febrile phase (days 0-5): fever, myalgia, headache
2. Critical phase (days 5-7): plasma leakage, shock risk
3. Recovery phase (days 7-10): fluid reabsorption, potential pulmonary edema if over-resuscitated

Most deaths occur during the critical phase from inadequate fluid resuscitation or during recovery from fluid overload 2, 3. Vigilance during both periods is essential.